Pro-Pharmaceuticals, Inc. Announces Significant Advance in Defining DAVANAT(R)'s Mechanism of Action Based on Experiments Done at the University of Minnesotaand the Ludwig Institute For Cancer Research (LICR) in Brussels, Belgium

Bookmark and Share

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC: PRWP), a developer of Galectin-targeting, carbohydrate therapeutic compounds to treat cancer and fibrosis, today announced it has made significant advances in determining the mechanism of action for its lead drug DAVANATĀ®. Recent studies conducted by Dr. Kevin Mayo at the University of Minnesota demonstrate DAVANATĀ® binds to Galectin-1, a receptor that controls angiogenesis of cancer tumors. Angiogenesis, the ability to form new blood vessels, represents a critical step in tumor development through which the tumor establishes an independent blood supply, consequently facilitating tumor growth.

Back to news